Carbenicillin Disodium
FDA-approved product (injectable, injection), marketed as Geopen, Pyopen.
- Registered studies
- 1
- Lab records
- 10
- Pathogens at ≥40%
- 1 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Bacterial disease
Indications ChEMBL records as approved, from FDA and DailyMed labels.
- WHO therapeutic group
- Penicillins with extended spectrum
- Anti-infective classification
- Classified as an existing antimicrobial.WHO ATC J01CA03
Repurposing investigation
Carbenicillin Disodium is already an antimicrobial, so it is not counted among the repurposing candidates. Its AI-predicted activity is shown below for reference.
AI-predicted activity
AI prediction · nothing measured- MRSA75.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
- E. coli5.3% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
- K. pneumoniae6.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
- M. tuberculosis34.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
1registered study names this medicine, for any condition. See them below.
Experimental
- MRSA: measured active in 3 of 5 lab records
- E. coli: measured active in 0 of 3 lab records
- K. pneumoniae: measured active in 0 of 2 lab records
Show the 10 laboratory records, with sources
Loading records…
“Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.
Docking
Computational · nothing measuredAutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Carbenicillin Disodium with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- Ozanimod HydrochlorideExisting use: Multiple sclerosis, Relapsing-remitting multiple sclerosis, Ulcerative colitis66.8% AI-predicted activityagainst MRSA7 registered studies
- Micafungin SodiumExisting use: Candidiasis66.8% AI-predicted activityagainst MRSA50+ registered studies
- AbemaciclibExisting use: Breast cancer, Breast carcinoma, Breast neoplasm and 3 more66.4% AI-predicted activityagainst MRSA50+ registered studies
- RisperidoneExisting use: Aggressive behavior, Autism, Bipolar disorder and 4 more66.4% AI-predicted activityagainst MRSA50+ registered studies
- Lazertinib MesylateExisting use: Non-small cell lung carcinoma66.1% AI-predicted activityagainst MRSANo documented evidence found
- Desmopressin AcetateExisting use: Central diabetes insipidus, Diabetes insipidus, Enuresis and 5 more65.8% AI-predicted activityagainst MRSA50+ registered studies
- Terazosin HydrochlorideExisting use: Benign prostatic hyperplasia65.8% AI-predicted activityagainst MRSA41 registered studies
- VemurafenibExisting use: Cancer, Cutaneous melanoma, Melanoma and 2 more65.8% AI-predicted activityagainst MRSA50+ registered studies
- Caspofungin AcetateExisting use: Aspergillosis, Candidemia, Candidiasis and 1 more65.5% AI-predicted activityagainst MRSA50+ registered studies
- VenetoclaxExisting use: Cancer, Chronic lymphocytic leukemia, Neoplasm65.5% AI-predicted activityagainst MRSA50+ registered studies
- Larotrectinib SulfateExisting use: Abdominal Neoplasms, Cancer, Metastasis and 1 more65.4% AI-predicted activityagainst MRSA5 registered studies
- SirolimusExisting use: Adenoma sebaceum, Angiofibroma, Cancer and 5 more65.2% AI-predicted activityagainst MRSA50+ registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
Patients Response to Early Switch To Oral:Osteomyelitis Study
NCT02099240 · start 2014-03-06
Registered record
- Registry ID
- NCT02099240
- Conditions
- Osteomyelitis
- Interventions
- oral antibiotics; intravenous antibiotics
- Study type
- INTERVENTIONAL
- Phase
- Early phase 1
- Registry status
- Terminated
- Start
- 2014-03-06
- Completion
- 2018-11-07
- Enrolment
- 11
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionOsteomyelitisInterventionoral antibiotics; intravenous antibioticsPhaseEarly phase 1Registry statusTerminated